Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H23N5O4 |
| Molecular Weight | 361.3956 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=N)C1=CC=C(C=C1)N2C[C@@H](CN3CCN(CC(O)=O)CC3)OC2=O
InChI
InChIKey=BXTGCIBGRDGLNI-CQSZACIVSA-N
InChI=1S/C17H23N5O4/c18-16(19)12-1-3-13(4-2-12)22-10-14(26-17(22)25)9-20-5-7-21(8-6-20)11-15(23)24/h1-4,14H,5-11H2,(H3,18,19)(H,23,24)/t14-/m1/s1
Gantofiban (or EMD 122 347) is an oral double prodrug of the drug, EMD 132338 and is GPIIb/IIIa antagonist. The drug participated in phase II clinical trials in Japan in patients with thrombosis. However, in May 2004, Yamanouchi, the developing company, announced that the study was discontinued. Besides gantofiban was involved in phase II trials, like a treatment option in patients with the acute coronary syndrome. However, further information is not available.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9950809
Created by
admin on Sat Dec 16 19:50:15 GMT 2023 , Edited by admin on Sat Dec 16 19:50:15 GMT 2023
|
PRIMARY | |||
|
9Y2SN3W6A3
Created by
admin on Sat Dec 16 19:50:15 GMT 2023 , Edited by admin on Sat Dec 16 19:50:15 GMT 2023
|
PRIMARY | |||
|
167364-01-4
Created by
admin on Sat Dec 16 19:50:15 GMT 2023 , Edited by admin on Sat Dec 16 19:50:15 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
